サインイン

Mayo Clinic, Rochester

3 ARTICLES PUBLISHED IN JoVE

Cancer Research

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Rosalie M. Sterner^1,2, Michelle J. Cox³, Reona Sakemura³, Saad S. Kenderian^2,3

¹Mayo Clinic Medical Scientist Training Program, Mayo Clinic College of Medicine and Science, ²Department of Immunology, Mayo Clinic, ³Division of Hematology, Mayo Clinic

Here, we present a protocol to genetically edit CAR-T cells via a CRISPR/Cas9 system.

Cancer Research

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [¹⁸F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Reona Sakemura^1,2, Michelle J. Cox^1,2, Aditya Bansal³, Claudia Manriquez Roman^1,2,4,5, Mehrdad Hefazi^1,2, Cynthia J. Vernon³, Dianna L. Glynn³, Mukesh K. Pandey³, Timothy R. DeGrado³, Elizabeth L. Siegler^1,2, Saad S. Kenderian^1,2,5,6

¹T Cell Engineering, Mayo Clinic, ²Division of Hematology, Mayo Clinic, ³Department of Radiology, Mayo Clinic, ⁴Regenerative Sciences PhD, Mayo Clinic, ⁵Department of Molecular Medicine, Mayo Clinic, ⁶Department of Immunology, Mayo Clinic

This protocol describes the methodology for non-invasively tracking T cells genetically engineered to express chimeric antigen receptors in vivo with a clinically available platform.

Cancer Research

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Claudia Manriquez Roman^1,2,3,4,5, R. Leo Sakemura^1,2, Brooke L. Kimball^1,2, Fang Jin⁶, Roman H. Khadka⁶, Mohamad M. Adada^1,2, Elizabeth L. Siegler^1,2, Aaron J. Johnson⁶, Saad S. Kenderian^1,2,6

¹T Cell Engineering Laboratory, Mayo Clinic, Rochester, ²Division of Hematology, Mayo Clinic, Rochester, ³Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, ⁴Department of Molecular Medicine, Mayo Clinic, Rochester, ⁵Regenerative Sciences PhD Program, Mayo Clinic, Rochester, ⁶Department of Immunology, Mayo Clinic, Rochester

Here, we describe a protocol in which an acute lymphoblastic leukemia patient-derived xenograft model is used as a strategy to assess and monitor CD19-targeted chimeric antigen receptor T cell-associated toxicities.